Lyell Immunopharma, Inc. — Director's Dealing 2024

Nov 1, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2024-10-31

Reporting Person: Ramachandra Sumant (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-31	Option (right to buy)	$0.9603	A	260000	Acquired	2034-10-30	Common Stock (260000)	Direct

Footnotes

F1: One thirty-sixth (1/36th) of the shares of common stock subject to the option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the reporting person providing service through the applicable vesting date.